VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 358,500 shares of the biotechnology company's stock, valued at approximately $19,707,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.19% of BioMarin Pharmaceutical as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in BMRN. Rise Advisors LLC purchased a new position in shares of BioMarin Pharmaceutical in the first quarter worth $30,000. Farther Finance Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 95.9% in the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after buying an additional 211 shares during the period. V Square Quantitative Management LLC purchased a new position in shares of BioMarin Pharmaceutical in the second quarter worth $25,000. Brooklyn Investment Group increased its stake in shares of BioMarin Pharmaceutical by 2,250.0% in the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock worth $40,000 after buying an additional 540 shares during the period. Finally, Banque Transatlantique SA purchased a new position in shares of BioMarin Pharmaceutical in the first quarter worth $71,000. 98.71% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
BMRN has been the topic of several analyst reports. Wall Street Zen downgraded shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 11th. JPMorgan Chase & Co. lifted their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an "overweight" rating in a research note on Thursday, October 9th. Wolfe Research set a $95.00 price objective on shares of BioMarin Pharmaceutical and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Wedbush reissued an "outperform" rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. Finally, HC Wainwright initiated coverage on shares of BioMarin Pharmaceutical in a research report on Monday, September 8th. They set a "neutral" rating and a $60.00 price objective on the stock. Thirteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $93.26.
Read Our Latest Stock Analysis on BMRN
BioMarin Pharmaceutical Stock Performance
Shares of BMRN stock opened at $53.29 on Monday. BioMarin Pharmaceutical Inc. has a 12 month low of $51.56 and a 12 month high of $73.51. The stock has a market cap of $10.23 billion, a PE ratio of 15.81, a price-to-earnings-growth ratio of 0.67 and a beta of 0.33. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The company's fifty day moving average price is $55.66 and its 200-day moving average price is $57.42.
About BioMarin Pharmaceutical
(
Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
